Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody

British Journal of Haematology

Volumn 140, Issue 3, 2008, Pages 303-312

  Bleeker, Wim K ^a   Munk, Martin E ^b   Mackus, Wendy J M ^a   Van Den Brakel, Jeroen H N ^a   Pluyter, Marielle ^a   Glennie, Martin J ^c   Van De Winkel, Jan G J ^a,d   Parren, Paul W H I ^a  

^a GENMAB   (Netherlands)

^b Genmab   (Denmark)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Animal model; Antibody therapy; B cells; Leukaemia

Indexed keywords

OFATUMUMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DAUDI CELL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MALE; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; B-LYMPHOCYTES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL; MACACA FASCICULARIS; MICE; MICE, SCID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 38349138517     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06916.x     Document Type: Article

References (27)

1. Berinstein, N.L., Grillo-Lopez, A.J., White, C.A., Bence-Bruckler, I., Maloney, D., Czuczman, M., Green, D., Rosenberg, J., McLaughlin, P. Shen, D. (1998) Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Annals of Oncology, 9, 995 1001.
2. Bleeker, W.K., Teeling, J.L. Hack, C.E. (2001) Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood, 98, 3136 3142.
3. Carter, P.J. (2006) Potent antibody therapeutics by design. Nature Reviews of Immunology, 6, 343 357.
4. Clynes, R.A., Towers, T.L., Presta, L.G. Ravetch, J.V. (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Medicine, 6, 443 446.
5. Coiffier, B., Tilly, H., Pedersen, L.M., Plesner, T., Frederiksen, H., van Oers, M.H.J., Wooldridge, J., Kloczko, J., Holowiecki, J., Hellmann, A., Walewski, J.J., Flensburg, M.F., Petersen, J. Robak, T. (2005) HuMax CD20 fully human monoclonal antibody in chronic lymphocytic leuchemia. Early results from an ongoing Phase I/II Clinical Trial. Blood (ASH Annual Meeting Abstracts), 106, 448.
6. Cragg, M.S. Glennie, M.J. (2004) Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood, 103, 2738 2743.
7. De Vita, S. Quartuccio, L. (2006) Treatment of rheumatoid arthritis with rituximab: an update and possible indications. Autoimmunity Reviews, 5, 443 448.
8. Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M. Golay, J. (2003) Complement activation determines the therapeutic activity of rituximab in vivo. Journal of Immunology, 171, 1581 1587.
9. Fishwild, D.M., O'Donnell, S.L., Bengoechea, T., Hudson, D.V., Harding, F., Bernhard, S.L., Jones, D., Kay, R.M., Higgins, K.M., Schramm, S.R. Lonberg, N. (1996) High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nature Biotechnology, 14, 845 851.
10. Glennie, M.J. (2000) Signalling antibodies for the treatment of neoplastic disease. Disease Markers, 16, 63.
11. Glennie, M.J. van de Winkel, J.G. (2003) Renaissance of cancer therapeutic antibodies. Drug Discovery Today, 8, 503 510.
12. Golay, J., Cittera, E., Di Gaetano, N., Manganini, M., Mosca, M., Nebuloni, M., van Rooijen, N., Vago, L. Introna, M. (2006) The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica, 91, 176 183.
13. Gong, Q., Ou, Q., Ye, S., Lee, W.P., Cornelius, J., Diehl, L., Lin, W.Y., Hu, Z., Lu, Y., Chen, Y., Wu, Y., Meng, Y.G., Gribling, P., Lin, Z., Nguyen, K., Tran, T., Zhang, Y., Rosen, H., Martin, F. Chan, A.C. (2005) Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. Journal of Immunology, 174, 817 826.
14. Gordan, L.N., Grow, W.B., Pusateri, A., Douglas, V., Mendenhall, N.P. Lynch, J.W. (2005) Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. Journal of Clinical Oncology, 23, 1096 1102.
15. Grillo-Lopez, A.J., White, C.A., Dallaire, B.K., Varns, C.L., Shen, C.D., Wei, A., Leonard, J.E., McClure, A., Weaver, R., Cairelli, S. Rosenberg, J. (2000) Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Current Pharmaceutical Biotechnology, 1, 1 9.
16. Hiddemann, W., Buske, C., Dreyling, M., Weigert, O., Lenz, G. Unterhalt, M. (2006) Current management of follicular lymphomas. British Journal of Haematology, 00, 00.
17. Lammerts van Bueren, J.J., Bleeker, W.K., Bogh, H.O., Houtkamp, M., Schuurman, J., van de Winkel, J.G. Parren, P.W. (2006) Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Research, 66, 7630 7638.
18. Lin, Y.S., Nguyen, C., Mendoza, J.L., Escandon, E., Fei, D., Meng, Y.G. Modi, N.B. (1999) Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. Journal of Pharmacology and Experimental Therapeutics, 288, 371 378.
19. Maloney, D.G., Liles, T.M., Czerwinski, D.K., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A. Levy, R. (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood, 84, 2457 2466.
20. van Oers, M.H., Klasa, R., Marcus, R.E., Wolf, M., Kimby, E., Gascoyne, R.D., Jack, A., Van't Veer, M., Vranovsky, A., Holte, H., van Glabbeke, M., Teodorovic, I., Rozewicz, C. Hagenbeek, A. (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood, 108, 3295 3301.
21. Press, O.W., Farr, A.G., Borroz, K.I., Anderson, S.K. Martin, P.J. (1989) Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Research, 49, 4906 4912.
22. Sell, S. Fahey, J.L. (1964) Relationship between gamma-globulin metabolism and low serum gamma-globulin in germfree mice. Journal of Immunology, 93, 81 87.
23. Sieber, T., Schoeler, D., Ringel, F., Pascu, M. Schriever, F. (2003) Selective internalization of monoclonal antibodies by B-cell chronic lymphocytic leukaemia cells. British Journal of Haematology, 121, 458 461.
24. Teeling, J.L., French, R.R., Cragg, M.S., Van Den Brakel, J., Pluyter, M., Huang, H., Chan, C., Parren, P.W., Hack, C.E., Dechant, M., Valerius, T., Van De Winkel, J.G. Glennie, M.J. (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood, 104, 1793 1800.
25. Teeling, J.L., Mackus, W.J., Wiegman, L.J., van den Brakel, J.H., Beers, S.A., French, R.R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J.W., Parren, P.W., Glennie, M.J. van de Winkel, J.G. (2006) The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. Journal of Immunology, 177, 362 371.
26. Vugmeyster, Y., Howell, K., McKeever, K., Combs, D. Canova-Davis, E. (2003) Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys. International Immunopharmacology, 3, 1477 1481.
27. Waldmann, T.A. Strober, W. (1969) Metabolism of immunoglobulins. Progress in Allergy, 13, 1 110.